ライフサイエンスコーパス: peripheral edema

1 in congestive heart failure, arrhythmia, and peripheral edema.

2 The most common toxicities were fatigue and peripheral edema.

3 olitinib were nausea, fatigue, vomiting, and peripheral edema.

4 anxiety, pharyngitis, sinus congestion, and peripheral edema.

5 ely lead to pulmonary congestion, ascites or peripheral edema.

6 administration was associated with increased peripheral edema.

7 rse vasodilatory effects such as headache or peripheral edema.

8 d reductions in the presence and severity of peripheral edema.

9 ual hallucinations (15 [23.8%] vs 1 [1.7%]), peripheral edema (15 [23.8%] vs 0), and dizziness (14 [2

10 europathy, 3% and 0.8%; fatigue, 5% and 12%; peripheral edema, 3.8% and 1.5%; and diarrhea, 2% and 10

11 a total of 6394 composite renal events (2670 peripheral edema, 3489 hypertension, 235 renal dysfuncti

12 e events in zibotentan-treated patients were peripheral edema (52.7%), diarrhea (35.4%), alopecia (33

13 , and 5% in arms A, B, and C, respectively), peripheral edema (71%, 51%, and 22% in arms A, B, and C,

14 re frequent with C25; peripheral neuropathy, peripheral edema, alopecia, and nail disorders were more

15 d anticonvulsants; xerostomia with TCAs; and peripheral edema and burning sensation with pregabalin a

16 s, which were accompanied by improvements in peripheral edema and functional status.

17 ted that for rofecoxib the adverse risks for peripheral edema and hypertension were evident by the en

18 onist treatment of humans is associated with peripheral edema and increased heart failure.

19 er nonhematologic toxicities, which included peripheral edema and neuropathy, are uncommon, and the a

20 Because myocardial and peripheral edema and systemic hypotension occur frequent

21 Peripheral edema and weight gain were observed in two of

22 ld adverse effects included malaise/fatigue, peripheral edema, and hyperglycemia.

23 Somnolence, dizziness, ataxia, peripheral edema, and infection were all more frequent i

24 Neutropenia, peripheral edema, and liver function test abnormalities

25 She decompensated with jaundice, peripheral edema, ascites, encephalopathy, coagulopathy,

26 (or lymphadenopathy), endocrinopathy, edema (peripheral edema, ascites, or effusions), and skin chang

27 with substantial concomitant hemorrhage and peripheral edema by E17.5dpc, resulting in mortality imm

28 body weight (days 1 and 7 or discharge), and peripheral edema (day 7 or discharge).

29 patients were skin-related toxicity, nausea, peripheral edema, diarrhea, pruritis, and fatigue.

30 The most common adverse events included peripheral edema, disease progression, and peripheral is

31 verse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across arms).

32 th anemia (grade 1 to 2, 35%; grade 3, 10%), peripheral edema (grade 1 to 2, 37%; grade 3, 2%), and f

33 up than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia

34 rial fibrillation, diabetes mellitus, rales, peripheral edema, higher New York Heart Association clas

35 Rash, peripheral edema, hyperglycemia, and hyperlipidemia were

36 All NSAIDs may produce peripheral edema, hypertension, and potentiate warfarin.

37 were associated with hepatic congestion and peripheral edema, intracardiac thrombi, and premature mo

38 acral erythema (n = 1), neuropathy (n = 1), peripheral edema (n = 1), and diarrhea (n = 1).

39 Side effects of IL-11 were mild (peripheral edema, n = 7; conjunctival injection, n = 7;

40 function, and this could explain some of the peripheral edema noted clinically with these agents.

41 Peripheral edema occurred in 9% of subjects receiving pl

42 w the clinical components of congestion (eg, peripheral edema, orthopnea) contribute to outcomes afte

43 ecoxib was associated with increased risk of peripheral edema (RR, 1.43; 95% CI, 1.23-1.66), hyperten

44 macitentan than with placebo were headache, peripheral edema, skin ulcer, anemia, upper respiratory

45 ted with urinary retention, arthralgias, and peripheral edema, subsequently developed acute lower-ext

46 age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, serum sodium,

47 ight gain, pleural or pericardial effusions, peripheral edema, thromboembolic events, and intermitten

48 2 pillows=2 points, <2 pillows=0 points) and peripheral edema (trace=0 points, moderate=1 point, seve

49 insufficiency manifested by new ascites and peripheral edema, treated with diuretics, a low-salt die

50 Marked ascites out of proportion to peripheral edema usually develops as a typical feature o

51 Mild peripheral edema was seen in 15% of patients and was tre

52 ates were similar, and a higher incidence of peripheral edema was the only apparent side effect of fe

53 rn after being linked with increased risk of peripheral edema, weight gain, and adverse cardiovascula

54 Rash, diarrhea, and peripheral edema were the most common toxic effects in t

55 s, such as rhinitis, headache, asthenia, and peripheral edema, were reversible on drug discontinuatio